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Miltefosine (Milt) was originally synthesized as an antineoplastic agent but this phospholipid drug is
now clinically used as an antiprotozoal compound. We demonstrate here that Milt reduces replication
of HIV-1 in cocultures of human dendritic cells (DCs) and CD4þ T cells. This phenomenon is due to a
rapid secretion of soluble factors by DCs. We present evidence that the Milt-mediated repression in
virus production is associated with induction of type-I interferon (IFN) in DCs. The Milt-dependent
diminution in HIV-1 production was not totally abrogated by B18R, a vaccinia virus-encoded
neutralizing type-I IFN receptor, which suggests the involvement of another yet to be identiﬁed
soluble factor. Altogether, these results suggest that a therapy with Milt when used to control
protozoan infections in individuals also carrying HIV-1 might also help to limit viral load. Additional
studies are warranted to estimate the exact therapeutic potential of Milt as an anti-HIV-1 agent.
& 2012 Elsevier Inc. All rights reserved.Introduction
The emergence of the acquired immunodeﬁciency syndrome
(AIDS) epidemic in the early 1980s has changed dramatically the
disease pattern caused by Leishmania parasites. For example,
species that traditionally caused one type of disease have been
shown to be capable of causing other types of diseases. The
protozoan parasite Leishmania is highly prevalent in many areas
of the world and in particular visceral leishmaniasis (VL) is now
becoming of higher clinical importance in individuals infected
with human immunodeﬁciency virus type-1 (HIV-1) because the
distribution of both human pathogens overlaps in various parts of
the world (Alvar et al., 2008). Furthermore, leishmaniasis’ classi-
ﬁcation as a childhood disease has been drastically altered due to
HIV-1 and Leishmania co-infections. There is also a growing
consensus that VL has emerged as an important opportunistic
infection in AIDS patients (Alvar et al., 1997; Tremblayet al., 1996;
Wolday et al., 1999).
The major challenge in dually infected patients is the admin-
istration of a successful treatment regimen during the acute
phase of the disease. The situation is further complicated by the
fact that HIV-1-positive individuals show higher rates of drug
toxicity and relapses, as well as lower cure rates with initialll rights reserved.
Infectiologie, RC709, Centre
Boul. Laurier, Que´bec (QC),
a (M.J. Tremblay).treatment as comparison to seronegative patients. First-line drugs
for the treatment of VL in both HIV-1-infected and non-infected
patients are the lipid formulations of amphotericin B, pentavalent
antimonials and miltefosine (Alvar et al., 2008). However, several
studies in co-infected individuals have shown only moderate
success rates with regard to initial cure and relapses.
Miltefosine (Milt) is a phosphorylcholine ester of hexadecanol
which is acting as a membrane-active synthetic ether-lipid
analog. This compound was originally discovered and synthesized
as an antineoplastic, particularly active against breast cancer
metastases. Milt has been recently found to be highly active
against Leishmania species both in in vitro and in vivo studies
(Croft et al., 1987; Murray and Delph-Etienne, 2000; Sundar et al.,
1998). The expanded use of Milt for treating VL is due to its
convenient oral administration route, the increasing leishmanial
resistance to antimonials and the unaffordable cost of liposomal
amphotericin B. It has been reported that Milt is effective at
controlling Leishmania parasitemia in both immunodeﬁcient
BALB/c and nude mice (Le Fichoux et al., 1998; Murray and
Delph-Etienne, 2000). This pre-clinical information has supported
its general use in individuals infected also with HIV-1 because
these are known to be immunodeﬁcient. Indeed, Milt has been
used for the treatment of VL in AIDS patients and has also been
employed with some success in cases with recurrent leishmaniasis
in HIV-1-infected individuals (Rihl et al., 2006; Schraner et al.,
2005). Interestingly, a number of reports have demonstrated that
Milt exerts signiﬁcant immunomodulatory properties in different
cell types (Eue, 2002; Hochhuth et al., 1992).
R. Garg, M.J. Tremblay / Virology 432 (2012) 271–276272It is now well accepted that HIV-1 mainly infects CD4þ T cells
but can also replicate in other cell subpopulations such as
macrophages and dendritic cells (DCs) (Coleman and Wu, 2009;
Wu and KewalRamani, 2006). DCs are potent and versatile
antigen-presenting cells and recent evidence suggests that they
play a pivotal role in establishment and dissemination of HIV-1
infection. The infection process seems to be facilitated by virtue of
DCs being the initial target cell type of HIV-1 and of their unique
capacity to migrate from virus entry sites in the periphery to the T
cell-rich areas in human lymphoid tissues. Moreover, an intimate
contact between DCs and CD4þ T cells has been shown to
promote a very efﬁcient transmission of HIV-1 by locally con-
centrating virus, viral receptor and coreceptors, as well as certain
adhesion molecules.
It is of interest to note that it has been shown that Milt reduces
HIV-1 production in macrophages via downstream activation of
Akt kinase (Chugh et al., 2008). Since DCs are crucial actors in
HIV-1 mucosal transmission and the overall pathogenesis of the
disease and given that CD4þ T cells act as a major cellular
reservoir for HIV-1, we analyzed the capacity of Mitl to affect
HIV-1 propagation in cocultures made of human immature
monocyte-derived DCs and autologous CD4þ T cells. We report
here that Milt diminishes HIV-1 production in such cocultured
cells. Furthermore, we provide evidence that the Milt-dependent
reduction in virus replication is mainly affecting virus production
in CD4þ T cells and is at least partly linked with secretion of type-
I interferon by DCs.Results
Milt reduces HIV-1 replication in cocultures of iDCs and CD4þ T
cells. Milt is currently one of the ﬁrst-line drug for the treatment
of VL in HIV-1-infected and non-infected patients. In an attempt
to deﬁne whether Milt can possibly affect the life cycle of HIV-1,
we studied its effect on virus replication in the context of
cocultures made of iDCs and autologous CD4þ T cells. To this
end, iDCs were initially pulsed with fully competent R5-tropic
virions (i.e. NL4-3Balenv) and next exposed to increasing doses of
Milt. Finally, immature monocyte-derived DCs (iDCs) were cocul-
tured with autologous CD4þ T cells. Results showed a statistically
signiﬁcant dose-dependent inhibition of HIV-1 replication in such
cocultured cells (Fig. 1). It should be noted that Milt and B18RFig. 1. HIV-1 replication in human cocultured cells is reduced by Milt. First, iDCs
were pulsed for 60 min with NL4-3Balenv and either left untreated (Ctrl) or
treated with the listed concentrations of Milt. Second, cells were cocultured with
autologous CD4þ T cells and virus production was estimated by measuring p24
levels in the culture supernatants at the indicated time points. Virus production at
day 2 following initiation of the coculture is depicted in the small insert (upper left
part). Data shown represent the means7SEM of triplicate samples and are
representative of six independent experiments. Asterisks denote statistically
signiﬁcant differences from the cells infected with HIV-1 only (*Po0.05;
**Po0.01).have no effect on HIV-1 replication in CD4þ T cells in absence of
iDCs (data not shown). The colorimetric MTS cell proliferation
assay revealed that the observed reduction in virus production is
not due to cell toxicity since cellular viability remains the same in
the presence of all tested concentrations of Milt (data not shown).
Moreover, similar observations were made when using a CFSE-
based viability and proliferation test (data not shown).
Milt represses virus replication in CD4þ T cells. We next tried to
shed light on the mechanism(s) by which Milt can reduce HIV-1
replication in human DCs/T-cell cocultures. First, iDCs were pre-
treated with the HIV-1 reverse transcriptase inhibitor efavirenz
(EFV) during the virus pulsing period. This treatment will abro-
gate de novo virus production in iDCs without altering transfer of
viruses located on their surface or within their endosomal
apparatus and the subsequent replication in CD4þ T cells. This
treatment completely abolished virus production in iDCs cultured
alone and a reduction in HIV-1 replication was also seen in
cocultured cells (data not shown). Interestingly, a comparable
diminution in virus production was detected in both untreated
and EFV-treated cocultures exposed to Milt (Fig. 2A). Therefore, it
can be proposed that Milt is not modulating susceptibility of iDCs
to virus infection and is thus most likely exerting its inhibitory
effect in CD4þ T cells. To provide more direct evidence on the
mechanism of action of Milt, iDCs were initially exposed to fully
infectious X4-tropic virions (i.e. NL4-3) and next cocultured with
autologous CD4þ T cells in presence of various concentrations of
Milt. The rationale for this experimental setup is based on theFig. 2. Milt modulates virus replication primarily in CD4þ T cells. (A) First, iDCs
were either left untreated (Ctrl) or treated with the antiviral agent EFV. Second,
cells were pulsed for 60 min with NL4-3Balenv and either left untreated (Ctrl) or
treated with the listed concentrations of Milt. Finally, iDCs were cocultured with
autologous CD4þ T cells. Virus production was estimated by measuring p24 levels
in the culture supernatants at 4 day following initiation of the coculture. (B) iDCs
were ﬁrst pulsed for 60 min with NL4-3 and either left untreated (Ctrl) or treated
with the listed concentrations of Milt. Next, cells were cocultured with autologous
CD4þ T cells and virus production was estimated by measuring p24 levels in the
culture supernatants at the indicated time points. Virus production at day
2 following initiation of the coculture is depicted in the small inserts (upper left
part). Data shown represent the means7SEM of triplicate samples and are
representative of ﬁve independent experiments. Asterisks denote statistically
signiﬁcant differences from the cells infected with HIV-1 only (*Po0.05;
**Po0.01).
Fig. 4. Milt-induced inhibition of virus replication in cocultured cells is partially
mediated by type-I IFN. (A) Cocultured cells were either left untreated or treated
with Milt for 6 h. Next, supernatants were collected and the levels of type-I IFN
were quantiﬁed through the use the HEK-BlueTM IFN-a/b cells. Data shown
represent the means7SEM of triplicate samples and are representative of ﬁve
independent experiments performed with different donors. (B) First, iDCs were
pulsed for 60 min with NL4-3Balenv and either left unexposed or exposed to Milt.
Next, iDCs were cocultured with autologous CD4þ T cells and either left untreated
or treated with B18R. Virus production was estimated by measuring p24 levels in
the culture supernatants at 4 day following initiation of the coculture. The results
shown represent the means7SEM of triplicate samples and are representative of
four separate experiments performed with different donors and are expressed as
relative viral production compared to cocultured cells exposed to HIV-1 but left
untreated with Milt and B18R. Asterisks denote statistically signiﬁcant data
(*Po0.05; **Po0.01).
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infection with X4-using variants (Pion et al., 2007). A dose-
dependent reduction in HIV-1 replication was still seen in
cocultures treated with Milt (Fig. 2B), which supports the idea
that Milt is affecting HIV-1 replication in CD4þ T cells. To validate
that HIV-1 production in CD4þ T cells is decreased upon a
coculture step with Milt-treated iDCs, we performed another set
of experiments where autologous CD4þ T cells were ﬁrst pulsed
with HIV-1 and then cocultured with iDCs either left untreated or
treated with Milt. Moreover, this set of experiments was also
aimed at assessing whether a cell-to-cell contact is needed to see
the Milt-mediated diminution in virus production. To do so, we
used permeable cell supports with a membrane pore size of
0.4 mm, which allows the crossing of virions and soluble factors
but not that of cells (Ramirez-Pineda et al., 2004). Results
depicted in Fig. 3 demonstrate that viral replication in CD4þ
T cells is similarly decreased by a coculture step with Milt-loaded
iDCs when cells are in a close physical contact. When iDCs were
physically separated from CD4þ T cells by a permeable mem-
brane, virus production was still diminished by a Milt treatment.
Thus, these results corroborate that the inhibitory effect of Milt in
cocultured cells is due to a repression of virus production in CD4þ
T cells and suggest that this process is caused by a Milt-mediated
release of a soluble factor by iDCs.
Milt-induced diminution of virus replication is partially mediated
by type-I IFN. It has been reported that Milt drives secretion of
IFN-g, TNF-a and IL-12 production from macrophages (Wadhone
et al., 2009). Consequently, we hypothesized that the observed
decrease in viral replication might be due to production by iDCs of
a soluble factor displaying an anti-HIV-1 activity in CD4þ T cells.
Given that type-I IFN is recognized as a powerful inhibitor of
in vitro and in vivo HIV-1 infection, our next series of investiga-
tions was aimed at assessing the capacity of Milt to induce
secretion of type-I IFN in iDCs with the use of the HEK-BlueTM
IFN-a/b indicator cell line. We observed that Milt acts indeed as a
good inducer of type-I IFN following treatment of human iDCs
(Fig. 4A). To validate the putative role of type-I IFN in the
observed Milt-dependent reduction of HIV-1 production in cocul-
tured cells, virus transfer experiments were performed with the
soluble vaccinia virus-encoded protein B18R that has been
demonstrated to inhibit the antiviral activity and cellular binding
of the type-I IFN of different mammalian species (e.g. IFN-a, IFN-b
and IFN-o) (Alcami et al., 2000; Symons et al., 1995). B18R was
added simultaneously with Milt in iDCs inoculated with HIV-1Fig. 3. Milt-dependent decrease in virus production seen in cocultured cells is due
to a soluble factor. First, CD4þ T cells were incubated for 2 h with NL4-3. Next,
CD4þ T cells were cocultured with iDCs in the presence of the listed concentration
of Milt for 4 day either in cell-to-cell contact or non-contact conditions. Virus
production was estimated by measuring p24 levels in the culture supernatants at
the indicated time points. Data shown represent the means7SEM of triplicate
samples and are representative of ﬁve independent experiments. Asterisks denote
statistically signiﬁcant differences from the cells infected with HIV-1 only
(**Po0.01).prior to initiation of the coculture step with autologous CD4þ T
cells. Data from Fig. 4B indicate that the Milt-mediated reduction
in de novo virus production seen in cocultured cells was asso-
ciated with secretion of type-I IFN. A higher concentration of B18R
did not further increase virus production (data not shown), thus
suggesting that the Milt-directed inhibition of virus production in
cocultured cells is not only due to production of type-I IFN by
iDCS but also to another unknown soluble factor.Discussion
Milt is an alkylphosphocholine analog that was originally
developed as an antitumor agent but proved to be clinically
ineffective against tumors, with intolerable adverse effects. Data
from animal and in vitro experimental studies suggest that Milt
displays also broad anti-fungal (e.g. Cryptococcus, Candida, Asper-
gillus and Fusarium) and anti-protozoal properties (e.g. Plasmo-
dium, Trypanosoma and Leishmania) (Blaha et al., 2006; Saraiva
et al., 2002; Widmer et al., 2006). Milt has been used in multiple
clinical trials and is now approved for treatment of leishmaniasis
in Germany, India and Columbia. Leishmaniasis is now recognized
as one of the leading HIV-1-associated opportunistic disease
in various countries. It is known that HIV-1-infected patients
who are receiving combined therapy have fewer opportunistic
infections. For example, it has been reported that the HIV-1
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of Leishmania parasites (Trudel et al., 2008; Valdivieso et al., 2010;
White et al., 2011). Milt tolerability and efﬁcacy in immunocom-
petent individuals have already been proven in earlier studies (Jha
et al., 1999; Le Fichoux et al., 1998; Murray and Delph-Etienne,
2000) but there is still many unanswered questions in immuno-
compromised persons. These reports together with the idea that
the efﬁcacy of drugs aimed at controlling each pathogen remains
largely undeﬁned in dually infected persons underlined the need
for further investigation.
DCs are central for the development of pathogen-speciﬁc
immune responses and are well equipped for activation of both
the innate and adaptive immune response (Mellman and
Steinman, 2001). It has been demonstrated that human pathogens
targeting DCs, such as HIV-1, have evolved strategies to impair DC
functions, thereby enhancing their capacity to persist and evade
immune surveillance. DCs have been reported as playing an
important role in the pathogenesis of AIDS, favoring both the
initial establishment and spread of the infection and the devel-
opment of antiviral immunity. In the present study, we investi-
gated whether Milt treatment can modulate HIV-1 replication
when iDCS are cocultured with autologous CD4þ T cells.
We provide the ﬁrst evidence showing that Milt represses HIV-
1 replication in iDCs-T-cell cocultures of human origin. To deﬁne
the precise contribution of de novo virus production from iDCs in
the Milt-dependent down-regulatory effect on HIV-1 replication,
coculture experiments were performed in presence of the anti-
retroviral compound EFV. Results with EFV-treated cells and
experiments performed with X4-tropic virions led us to conclude
that the Milt-directed effect in virus production is independent of
productive infection of iDCs. Interestingly, our data indicate also
that a close physical contact between Milt-treated iDCs and CD4þ
T cells is not necessary to diminish HIV-1 production, therefore
indicating that the observed reduction in virus replication is
achieved through the secretion of a soluble factor. This postulate
is supported by the previous observation that Milt induces
production of numerous cytokines such as TNF-a, GM-CSF, IL-12
and IFN-g (Beckers et al., 1994; Hochhuth et al., 1992; Wadhone
et al., 2009; Zeisig et al., 1995). The human IFN network is known
as one of the fastest responding branch of our immune defense to
control an invading pathogen. The IFN system is an extremely
powerful antiviral response that is capable of controlling most, if
not all, virus infections in the absence of adaptive immunity.
Type-I IFN (e.g. a and b) are produced by many cell types, while
type-II IFN (i.e. g) is more restricted since it is produced by
immune cells. Type-I IFN comprises a large group of molecules
that includes IFN-a and -b as well as IFN-o, -E, -t, -d and -k. The
IFN-a and -b genes are induced directly in response to viral
infection, whereas IFN-o, -E, -d and -k play less well-deﬁned
roles, such as regulators of maternal recognition in pregnancy. We
show here using HEK-BlueTM IFN a/b cells that the Milt-mediated
restriction of HIV-1 replication is due in part to an endogenous
production of type-I IFN. Indeed, this indicator cell line has
allowed us to determine that treatment of iDCs with Milt induces
a rapid production of type-I IFN (i.e. as early as 3 h following
exposure to the drug) reaching a peak at 6 h (data not shown).
Previous studies revealed that treatment of human cells with
type-I IFN restricts HIV-1 replication via blocking both early and
late stages of the virus replicative cycle (Agy et al., 1995; Baca-
Regen et al., 1994; Coccia et al., 1994; Shirazi and Pitha, 1992).
Treatment of iDCs with the type-I IFN-binding receptor B18R
conﬁrms the importance of such a soluble factor in the Milt-
dependent inhibitory effect on HIV-1 gene expression. However,
the Milt-mediated diminution of virus production was not totally
abrogated in the presence of the recombinant protein B18R,
therefore indicating that another soluble factor in addition totype-I IFN is involved in the inhibitory effect mediated by this
drug. Altogether our data suggest a partial role of type-I IFN in the
Milt-mediated inhibition of HIV-1 replication seen in a coculture
system consisting of iDCs and autologous CD4þ T cells.
It was shown previously that patients dually infected with
HIV-1 and Leishmania, who had experienced failure of standard
leishmaniasis treatment, displayed an initial response rate of 64%
and a cure rate of 43% during the ﬁrst treatment cycle with Milt
(Sindermann et al., 2004). Milt is now recognized as the ﬁrst oral
agent that appears to be highly effective and well tolerated for the
treatment of co-infected patients. The current work demonstrates
for the ﬁrst time that Milt can, in addition to its already known
anti-leishmanicidal properties, restrict also HIV-1 propagation
and shed light on the mechanisms by which this compound can
modulate virus replication. These results add new and interesting
in vitro insights into the possible inhibitory activity of Milt
against HIV-1 and suggest studying its efﬁcacy on others cell
targets (e.g. macrophages) to validate its use on a larger scale in
individuals co-infected with HIV-1 and Leishmania. However, the
precise clinical relevance of our present ﬁndings remains to be
determined.Material and methods
Reagents. Milt was obtained from Alexis Biochemicals (San
Diego, CA) while B18R was purchased from eBiosciences (San
Diego, CA). Recombinant human interleukin-2 (rhIL-2), EFV and
azidothymidine (AZT) were obtained from the NIH AIDS Reposi-
tory Reagent Program (Germantown, MD). Interferon-gamma
(IFN-g) and IL-4 were both purchased from R&D systems (Min-
neapolis, MN), whereas granulocyte macrophage-colony stimu-
lating factor (GM-CSF) was a generous gift from Cangene
(Winnipeg, MB). Lipopolysaccharide (LPS) and phytohemaggluti-
nin-L (PHA-L) were obtained from Sigma (St-Louis, MO). The
culture medium consisted of RPMI-1640 supplemented with
10% fetal bovine serum (FBS), penicillin G (100 U/mL), strepto-
mycin (100 U/mL) and glutamine (2 mM), which were all pur-
chased from Wisent (St-Bruno, QC), and primocine (Amaxa
Biosystems, Gaithersburg, MD).
Cells. Human embryonic kidney 293 T cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
10% FBS (Wisent, St-Bruno, QC). DCs were generated from mono-
cytes obtained from the blood of healthy donors. Brieﬂy, CD14þ
cells (i.e. monocytes) were isolated from peripheral blood mono-
nuclear cells, using a monocyte-positive selection kit according to
the manufacturer’s instructions (CD14-positive selection kit;
StemCell Technologies Inc., Vancouver, BC). Puriﬁed CD14þ cells
were cultured in RPMI-1640 medium supplemented with 10%
FBS, GM-CSF (1000 U/ml) and IL-4 (200 U/ml) for 7 day to obtain
iDCs as previously described (Gilbert et al., 2007). Autologous
CD4þ T cells were isolated with a negative selection kit (Stem Cell
Technologies) and activated with the mitogenic agent PHA-L (1
mg/ml) and IL-2 (30 U/ml) for 48 h prior to their use. HEK-BlueTM
IFN-a/b cells (InvivoGen, San Diego, CA) were maintained in
Dulbecco’s modiﬁed Eagle medium (Invitrogen) supplemented
with 10% FBS, glutamine (2 mM), penicillin G (100 U/ml) and
streptomycin (100 mg/ml). Culture media used for HEK-BlueTM
IFN-a/b cells was supplemented with 30 mg/ml of blasticidin and
100 mg/ml of Zeocin.
Viral preparations. Virus stocks were produced upon transient
calcium phosphate transfection of 293 T cells with full-length
infectious molecular clones NL4-3 (X4) (NIH AIDS Repository
Reagent Program) and NL4-3Balenv (R5) (Dornadula et al., 1999).
Virus stocks were normalized by using a sensitive in-house,
double-antibody sandwich enzyme-linked immunosorbent assay
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Viral preparations underwent a single freeze-thaw cycle before
being their use.
Virus transmission assays. First, iDCs were inoculated with
NL4-3 or NL4-3Balenv virions (10 ng of p24 per105 cells) for
60 min at 37 1C and unbound virus was eliminated by extensive
washes with phosphate-buffered saline (PBS). Next, iDCs were
either left untreated (used as a control) or treated with different
concentrations of Milt. Cells were then incubated with activated
CD4þ T cells at a 1:3 ratio (iDCs:CD4þ T cells). Viral production
was assayed by measuring the cell-free p24 content at different
time intervals. In some experiments, iDCs were treated with the
antiretroviral drug EFV (50 nM) for 30 min before pulsing with
fully competent HIV-1 particles. In some HIV-1 transfer studies,
permeable cell inserts with polycarbonate membranes (Trans-
wellTM, Corning Inc., Lowell, MA) (pore size: 1 mm) were used to
separate iDCs and CD4þ T cells. Brieﬂy, iDCs were either left
untreated or treated with Milt. Next, PHA-treated autologous
CD4þ T cells were pulsed with HIV-1 for 2 h, washed extensively
with PBS and transferred into permeable cell inserts and cocul-
tured with iDCs for 3 day. Virus production was assessed by
estimating the p24 content.
Quantiﬁcation of type-I IFN and blocking experiments. iDCs were
either left untreated or treated for 6 h with different doses of Milt.
Thereafter, levels of type-I IFN (i.e. IFN-a and -b) in cell-free
supernatants were determined through the use of HEK-BlueTM
IFNa/b cells according to the manufacturer’s protocol (Invivo-
Gen). These cells allow the detection of bioactive IFN-a and -b by
monitoring the activation of the ISGF3 pathway. HEK-BlueTM
IFNa/b cells are stably transfected with a SEAP promoter gene
under the control of the IFNa/b-inducible ISG54 promoter.
Stimulation of these cells with type-I IFN activates the JAK/STAT/
ISGF3 pathway and induces subsequently the secretion of SEAP in
the supernatant. A standard curve of IFN-a ranging from 1 to 250
Units/ml was used to quantify the amounts of type-I IFN released
in the culture medium. The type-I IFN inhibitor B18R (200 ng/ml),
a vaccinia virus-derived soluble receptor that blocks the effect
of biologically functional type-I IFN, was added to the culture
medium when initiating virus transmission experiment with Milt.
Statistical analysis. The statistical signiﬁcance of the results was
deﬁned by performing a one-way ANOVA analysis of variance
with Bonferroni’s multiple comparison tests and Dunnett’s post-
tests to compare treated versus untreated control samples. All
analyses were performed on raw data (i.e. p24 concentrations).
P values lower than 0.05 were considered statistically signiﬁcant.
InStat software (GraphPad Software version 5.04) was used for all
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